AGENUS INCAGENEarnings & Financial Report
Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and adjuvants designed for use with various vaccines. CPM development is a particularly fast-moving field, since early products have produced unprecedented clinical benefits for patients.
AGEN Q4 FY2025 Key Financial Metrics
Revenue
$34.2M
Gross Profit
N/A
Operating Profit
$14.4M
Net Profit
$-10.6M
Gross Margin
N/A
Operating Margin
42.1%
Net Margin
-31.0%
YoY Growth
27.5%
EPS
$0.09
AGENUS INC Q4 FY2025 Financial Summary
AGENUS INC reported revenue of $34.2M (up 27.5% YoY) for Q4 FY2025, with a net profit of $-10.6M (up 77.3% YoY) (-31.0% margin).
Key Financial Metrics
| Total Revenue | $34.2M |
|---|---|
| Net Profit | $-10.6M |
| Gross Margin | N/A |
| Operating Margin | 42.1% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
AGENUS INC Q4 FY2025 revenue of $34.2M breaks down across 2 segments, led by Non Cash Royalty Revenue at $31.1M (90.8% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Non Cash Royalty Revenue | $31.1M | 90.8% |
| Other | $3.2M | 9.2% |
AGENUS INC Revenue by Segment — Quarterly Trend
AGENUS INC revenue by segment across the last 4 reported quarters, showing how each business line (such as Non Cash Royalty Revenue and Other) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Non Cash Royalty Revenue | $31.1M | — | — | — |
| Other | $3.2M | — | $860.0K | $510.0K |
AGENUS INC Annual Revenue by Year
AGENUS INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $114.2M).
AGENUS INC Quarterly Revenue & Net Profit History
AGENUS INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $34.2M | +27.5% | $-10.6M | -31.0% |
| Q3 FY2025 | $30.2M | +20.4% | $63.9M | 211.4% |
| Q2 FY2025 | $25.7M | +9.3% | $-30.0M | -116.8% |
| Q1 FY2025 | $24.1M | -14.1% | $-26.4M | -109.6% |
| Q4 FY2024 | $26.8M | -68.0% | $-46.8M | -174.4% |
| Q3 FY2024 | $25.1M | +3.3% | $-67.2M | -267.7% |
| Q2 FY2024 | $23.5M | -7.1% | $-54.8M | -233.1% |
| Q1 FY2024 | $28.0M | +22.3% | $-63.5M | -226.6% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $28.0M | $23.5M | $25.1M | $26.8M | $24.1M | $25.7M | $30.2M | $34.2M |
| YoY Growth | 22.3% | -7.1% | 3.3% | -68.0% | -14.1% | 9.3% | 20.4% | 27.5% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $256.6M | $292.4M | $238.5M | $226.3M | $200.2M | $185.2M | $233.9M | $226.8M |
| Liabilities | $458.0M | $533.7M | $530.8M | $552.7M | $542.0M | $539.8M | $508.0M | $497.9M |
| Equity | $-201.4M | $-241.3M | $-292.3M | $-326.4M | $-341.8M | $-354.6M | $-274.1M | $-271.1M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-38.2M | $-38.2M | $-53.3M | $-28.7M | $-25.6M | $-20.2M | $-14.7M | $-16.6M |